Population pharmacokinetic meta-analysis of an intranasal fentanyl spray as a means to enrich pharmacokinetic information in patients with cancer breakthrough pain

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 9, 2012, Pages 665-677

  Kaessner, Nele ^a,b   Nave, Rüdiger ^a   Roepcke, Stefan ^a,b   Facius, Axel ^a,b   Lahu, Gezim ^a,b  

^a Nycomed: A Takeda Company   (Germany)

^b Takeda Pharmaceuticals International GmbH   (Switzerland)

Author keywords

Cancer; Intranasal fentanyl; Metaanalysis; Pain; Pharmacokinetics; PopPK

Indexed keywords

FENTANYL; OXYMETAZOLINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL EVALUATION; COMMON COLD; DENTAL SURGERY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; HAY FEVER; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; SEX DIFFERENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

ADMINISTRATION, INTRANASAL; AEROSOLS; ANALGESICS, OPIOID; AREA UNDER CURVE; BREAKTHROUGH PAIN; COMPUTER SIMULATION; FENTANYL; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NEOPLASMS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84866498292     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201737     Document Type: Article

References (19)

1. Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med. 2009; 12: 947-954. doi:10.1089/jpm.2009.0051 PubMed
2. Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010; 26: 1037-1045. doi:10.1185/03007991003694340 PubMed
3. Moore RA, Hand CW, McQuay HJ. Opiate metabolism and excretion. Baillieres Clin Anaesthesiol. 1987; 1: 829-858. doi:10.1016/S0950-3501(87)80038-7
4. Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S. Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography - mass spectrometry. Anesthesiology. 1984; 61: 73-77. PubMed
5. Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing thirdmolar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008; 30: 469-481. doi:10.1016/j.clinthera.2008.03.001 PubMed
6. Foster D, Upton R, Christrup L, Popper L. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother. 2008; 42: 1380-1387. doi:10.1345/aph. 1L168 PubMed
7. Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and break-through pain. J Opioid Manag. 2010; 6: 17-26. doi:10.5055/jom.2010.0001 PubMed
8. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with common cold. Poster No. 719, 6th Congress of the European Federation of IASP® Chapters (EFIC), September 9-12, 2009, Lisbon, Portugal.
9. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline. Poster No. 718, 6th Congress of the European Federation of IASP® Chapters (EFIC), September 9-12, 2009, Lisbon, Portugal.
10. Ariano RE, Duke PC, Sitar DS. Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol. 2001; 41: 757-763. doi:10.1177/ 00912700122010663 PubMed
11. Hudson RJ, Thomson IR, Henderson BT, Singh K, Harding G, Peterson DJ. Validation of fentanyl pharmacokinetics in patients undergoing coronary artery bypass grafting. Can J Anaesth. 2002; 49: 388-392. doi:10.1007/BF03017328 PubMed
12. Shafer SL, Varvel JR, Aziz N, Scott JC. Pharmacokinetics of fentanyl administered by computercontrolled infusion pump. Anesthesiology. 1990; 73: 1091-1102. doi:10.1097/00000542-199012000-00005 PubMed
13. Kaneda K, Han TH. Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: burns vs. non-burns. Burns. 2009; 35: 790-797. doi:10.1016/j.burns.2008.12.006 PubMed
14. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993; 21: 735-750. doi:10.1007/BF01113502 PubMed
15. Sahota T, Buil N, Hara K, Della Pasqua O. The Chicken and the Egg in Interoccasion Variability [Online]. PAGE 19 (2010) Abstr 1887 [cited 2011 Jun 01]; Available from: URL: http://www.pagemeeting.org/?abstract = 1887.
16. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic - pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992; 20: 511-528. doi:10.1007/BF01061469 PubMed
17. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58: 51-64. doi:10.1016/S0169-2607(98)00067-4 PubMed
18. Wählby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002; 4: E27 doi:10.1208/ps040427 PubMed
19. Nycomed Danmark ApS. Instanyl - Summary of Product Characteristics. European Medicines Agency web site: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR---Product-Information/human/000959/WC500033141.pdf. accessed 06 Feb 2012.